Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy + toripalimab + TAS-102 + regorafenib in later-line colorectal cancer
ChiCTR2600119059Phase 2Recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, trifluridine + tipiracil and regorafenib in colorectal cancer (CRC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
toripalimabtrifluridine + tipiracilregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600119059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119059.